Integrin-linked kinase at a glance

M Widmaier, E Rognoni, K Radovanac… - Journal of cell …, 2012 - journals.biologists.com
2002). They are non-covalently associated heterodimers consisting of a-and bsubunits. On
the cell surface, integrins exist in a conformation with either high (active) or low (inactive) …

Kindlin-2 cooperates with talin to activate integrins and induces cell spreading by directly binding paxillin

M Theodosiou, M Widmaier, RT Böttcher, E Rognoni… - Elife, 2016 - elifesciences.org
Integrins require an activation step prior to ligand binding and signaling. How talin and
kindlin contribute to these events in non-hematopoietic cells is poorly understood. Here we …

[HTML][HTML] Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction

S Ussar, M Moser, M Widmaier, E Rognoni… - PLoS …, 2008 - journals.plos.org
Kindler Syndrome (KS), characterized by transient skin blistering followed by abnormal
pigmentation, skin atrophy, and skin cancer, is caused by mutations in the FERMT1 gene …

Sorting nexin 17 prevents lysosomal degradation of β1 integrins by binding to the β1-integrin tail

RT Böttcher, C Stremmel, A Meves, H Meyer… - Nature cell …, 2012 - nature.com
Integrin functions are controlled by regulating their affinity for ligand, and by the efficient
recycling of intact integrins through endosomes. Here we demonstrate that the Kindlin …

Kindlin-1 controls Wnt and TGF-β availability to regulate cutaneous stem cell proliferation

E Rognoni, M Widmaier, M Jakobson, R Ruppert… - Nature medicine, 2014 - nature.com
Kindlin-1 is an integrin tail binding protein that controls integrin activation. Mutations in the
FERMT-1 gene, which encodes for Kindlin-1, lead to Kindler syndrome in man, which is …

[HTML][HTML] Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy

S Althammer, TH Tan, A Spitzmüller, L Rognoni… - … for immunotherapy of …, 2019 - Springer
Abstract Background Immune checkpoint therapies (ICTs) targeting the programmed cell
death-1 (PD1)/programmed cell death ligand-1 (PD-L1) pathway have improved outcomes …

[HTML][HTML] Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis

KE Steele, TH Tan, R Korn, K Dacosta, C Brown… - … for immunotherapy of …, 2018 - Springer
Background Immuno-oncology and cancer immunotherapies are areas of intense research.
The numbers and locations of CD8+ tumor-infiltrating lymphocytes (TILs) are important …

[HTML][HTML] Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis

M Widmaier, T Wiestler, J Walker, C Barker… - Modern …, 2020 - nature.com
Tumor programmed cell death ligand-1 (PD-L1) expression is a key biomarker to identify
patients with non-small cell lung cancer who may have an enhanced response to anti …

Mutually exclusive expression of CD73 and PDL1 in tumors from patients (pt) with NSCLC, gastroesophageal (GE) and urothelial bladder carcinoma (UBC).

P Martin, A Spitzmueller, S Wu, M Widmaier, R Korn… - 2017 - ascopubs.org
3079 Background: Tumors use multiple means of immune evasion, notably the programmed
death-1 (PD1)/PDL1 pathway. Anti-PD1/PDL1 therapy induces anti-tumor activity and has …

Integrative spatially-resolved, high-plex digital profiling enables characterization of complex immune biology in the tumor microenvironment of mesothelioma

C Ballesteros-Merino, M Widmaier, S Church… - 2018 - digitalcommons.providence.org
Background: Malignant mesothelioma is an aggressive cancer with poor prognosis and few
effective therapies. Since mesothelioma is derived from the mesothelium of the lung, we …